| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 Readout example | Phase 2 | — | Subscribe to access the data. | Nanomedicine | Dermatologic System | ||
Phase 2 Readout example | Phase 2 | — | Subscribe to access the data. | Nanomedicine | Dermatologic System | ||
Phase 2 Readout example | Phase 2 | — | Subscribe to access the data. | Nanomedicine | Dermatologic System |
Recent Updates
Recently added Catalysts
Tarsus Pharmaceuticals, Inc.$58.14
-6.82 (-10.63%)
D 35Pipeline Score Richly Valued Biotech · Commercial
Market Cap
2.68 B
EPS
-1.13
P/E Ratio
-
Value Trade
48.57 M
SEC Financials
Q1 2026Dilution Risk
Revenue
162.05 M
R&D Expenses
22.35 M
Operating CF
-24.65 M
Total Assets
581.13 M
Total Liabilities
232.18 M
Equity
348.95 M
D/E Ratio
12,345
-4.22 %
Week
-3.83 %
1 Month
-4.67 %
3 Month
-19.06 %
6 Month
95.17 %
5 Year
284.32 %
All Time
Cash Data
Cash Position
388.73 M
Monthly Burn
8.22 M
Runway
45.4 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
2.37 M
52 Week Range
38.51 - 85.25
% held by Insiders
6.13 %
% held by Institutions
103.59 %
Enterprise Value
2.38 B
Total Shares
42.54 M
Short %
12.33 %
Float Shares
36.67 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tarsus Pharmaceuticals, Inc.
314Total events
7Upcoming
69Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 7
2027
T2EU MAA Submission
On-track for potential European regulatory approval of preservative-free XDEMVY in 2027
Event history 307
Q3 2026
▲Enrollment UpdateTrial
On track to activate approximately 20 new Key Account Leaders by Q3 2026
Jun 2026
◆Oral PresentationPresentation
Tarsus management to participate in June 2026 investor conferences
May 19, 2026
May 14, 2026
▲Partnership / LicenseCorporate
Partnership with John Cena to raise awareness of Demodex blepharitis and XDEMVY
Demodex blepharitissource ↗
May 12, 2026
May 6, 2026
May 6, 2026
▲Trial InitiationTP-05 Low DoseTrial
Initiated Calliope Phase 2 trial of TP-05 for Lyme disease prevention
Lyme disease preventionsource ↗
May 6, 2026
▲FDA ApprovalXDEMVYApprovedFDA Decision
Regulatory approval in China for XDEMVY (TP-03) by Grand Pharmaceuticals
Demodex blepharitissource ↗
May 6, 2026
▲Milestone PaymentXDEMVYApprovedCorporate
$15 million milestone payment from Grand Pharmaceuticals for China approval
Demodex blepharitissource ↗
Drug Pipeline Intelligence
D35
Pipeline Score $166M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.1x
rNPV / MCap Top 46%
Small Cap (rank 493 of 911)
Percentile RankTarsus Pharmaceuticals, Inc. faces pipeline headwinds (35/100), with $256M risk-adjusted pipeline value, led by Low Dose TP-05 in Healthy Volunteer (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low Dose TP-05 Small molecule | Healthy Volunteer | Phase 2 | NCT05387083 | 14% | $97M | COMPLETED | 30 | - | - | Jun 26, 2024 | - | Sep 19, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TP-05 | Lyme disease prevention | Phase 2a | 2024-02-22 | Day 1: high dose mortality 97.0%, low dose mortality 92.0%, placebo mortality 5.0%; Day 30: high dose mortality 89.0%, low dose mortality 91.0%, placebo mortality 9.0% Read More | Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease Read More | |
TP-05 | Lyme disease prevention | Phase 2a | 2024-02-22 | Day 1: high dose mortality 97.0%, low dose mortality 92.0%, placebo mortality 5.0%; Day 30: high dose mortality 89.0%, low dose mortality 91.0%, placebo mortality 9.0% Read More | Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease Read More | |
TP-05 | Lyme disease prevention | Phase 2a | 2024-02-22 | Day 1: high dose mortality 97.0%, low dose mortality 92.0%, placebo mortality 5.0%; Day 30: high dose mortality 89.0%, low dose mortality 91.0%, placebo mortality 9.0% Read More | Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TARS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TARS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TARSTarsus to Participate in Upcoming June 2026 Investor Conferences
Tarsus Pharmaceuticals, Inc. announced its participation in several upcoming investor conferences in June 2026. The company aims to showcase its advancements in eye care and infectious disease prevention. Tarsus is also progressing its pipeline, including FDA-approved XDEMVY and other treatments in Phase 2 development.
Read more →TARSTarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals, Inc. has announced its participation in two upcoming investor conferences: the William Blair 46th Annual Growth Stock Conference and the 2026 Jefferies Global Healthcare Conference. The live webcasts will be accessible through the Tarsus website, where replays will also be available. The company is focused on innovating treatments in eye care and other therapeutic areas, with products like XDEMVY already approved and others in development.
Read more →TARSTarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
Tarsus Pharmaceuticals has partnered with John Cena to raise awareness about Demodex blepharitis, a common eyelid disease affecting around 25 million Americans. Cena shares his personal experience with the condition and the FDA-approved treatment, XDEMVY. The campaign aims to encourage individuals to prioritize their eye health and seek proper diagnosis and treatment.
Read more →TARSTarsus to Participate in Upcoming May 2026 Investor Conferences
Tarsus Pharmaceuticals, Inc. has announced its participation in upcoming investor conferences. The company is focused on advancing its pipeline, which includes FDA-approved XDEMVY for Demodex blepharitis and other treatments in development. These efforts highlight Tarsus's commitment to addressing high unmet needs in eye care and infectious disease prevention.
Read more →TARSTarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals reported strong first quarter 2026 financial results, with XDEMVY sales exceeding $145 million, marking an 85% increase year-over-year. The company reaffirmed its full-year sales guidance of $670-700 million and highlighted the growing adoption of XDEMVY among eye care professionals. Additionally, Tarsus initiated a Phase 2 trial for TP-05, an investigational oral tablet aimed at preventing Lyme disease.
Read more →TARSDocument Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements Generated first quarter XDEMVY net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffi
Tarsus Pharmaceuticals reported first quarter financial results for 2026, highlighting significant growth in net product sales of XDEMVY, which exceeded $145 million, representing an 85% year-over-year increase. The company reaffirmed its sales guidance for the full year, expecting between $670-700 million in sales. Tarsus also initiated a Phase 2 trial for TP-05, an investigational oral treatment for Lyme disease, with topline results anticipated in the first half of 2027. The firm maintains strong engagement within the ophthalmology sector as XDEMVY continues to gain traction among eye care professionals.
Read more →TARSTarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Tarsus Pharmaceuticals, Inc. will host a live webcast on May 6, 2026, to report its first quarter financial results and provide a corporate update. The company is focused on innovative treatments in eye care and infectious disease prevention. Tarsus has FDA approval for its product XDEMVY and is developing additional therapies in Phase 2.
Read more →TARSTarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
Tarsus Pharmaceuticals has initiated the Phase 2 Calliope trial for TP-05, an investigational oral therapy aimed at preventing Lyme disease. The trial will involve around 700 healthy adults and aims to complete enrollment during the 2026 tick season. Results are expected in the first half of 2027, marking a potential breakthrough in Lyme disease prevention.
Read more →TARSTP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
Tarsus Pharmaceuticals has received regulatory approval for TP-03 (lotilaner ophthalmic solution) 0.25% in China, leading to a $15 million milestone payment. This approval, achieved through Grand Pharmaceutical Group, marks a significant advancement in treating Demodex blepharitis, affecting over 40 million individuals in the region. Tarsus aims to support its partner in the upcoming product launch.
Read more →TARS▲ +7.8%on this newsshared move
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals reported a significant increase in net product sales for XDEMVY, reaching $451.4 million in 2025. The company is optimistic about the drug's peak sales potential, projected to exceed $2 billion. Tarsus is also advancing its pipeline with Phase 2 trials for TP-04 and TP-05. However, the company faces challenges, including ongoing financial losses and uncertainties regarding market opportunities.
Read more →TARSDocument Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements Generated full-year 2025 net product sales of XDEMVY of $451.4 million, an increase of more than 150% year-over
Tarsus Pharmaceuticals has reported a remarkable increase in net product sales for its XDEMVY eye drops, totaling $451.4 million in 2025, a rise of over 150% from the previous year. The company also announced plans for new clinical trials for its drugs TP-04 and TP-05, aiming to establish new treatment standards in ocular rosacea and Lyme disease prevention. Despite these successes, Tarsus reported a net loss of $66.4 million due to increased operational costs, particularly in sales and marketing expenditures. Moreover, the ongoing high gross-to-net discount highlights financial pressures despite strong sales growth.
Read more →TARSTarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
Tarsus Pharmaceuticals has appointed David E. I. Pyott, former CEO of Allergan, to its Board of Directors. Pyott's extensive experience in the biopharmaceutical industry is expected to aid Tarsus in scaling its lead product, XDEMVY, and advancing its pipeline. He expressed enthusiasm about contributing to Tarsus' growth and innovation in eye care.
Read more →TARSTarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
Tarsus Pharmaceuticals, Inc. will report its fourth quarter and full year 2025 financial results on February 23, 2026. The company will host a live webcast to discuss these results and provide a corporate update. Tarsus is known for its innovative treatments in eye care and infectious disease prevention, including its FDA-approved product XDEMVY.
Read more →TARSTarsus to Participate in Upcoming Investor Conference
Tarsus Pharmaceuticals will participate in a fireside chat at the BTIG 5th Annual Ophthalmology Day on December 1st. The event will be accessible via a live webcast, with a replay available shortly after. Tarsus is focused on innovative treatments in eye care and other therapeutic areas, including ongoing Phase 2 developments.
Read more →TARSTarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals reported strong financial results for Q3 2025, with XDEMVY sales of approximately $119 million, reflecting a 147% year-over-year increase. The company noted a 30% growth in weekly multi-patient prescribers, showcasing robust commercial momentum. Tarsus is also expanding its pipeline with new treatments targeting ocular rosacea and Lyme disease prevention.
Read more →TARSDocument Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements Delivered quarterly XDEMVY net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient
Tarsus Pharmaceuticals has reported significant financial progress for Q3 2025, with XDEMVY net sales approximately at $119 million, representing a 147% increase year-over-year. The company is also experiencing strong commercial momentum, marked by a 30% rise in prescribers for the product. The CEO highlighted ongoing efforts in category creation within eye care and plans for future trials targeting additional conditions like ocular rosacea. Despite some financial losses and rising expenses, Tarsus appears to be on a path of sustainable growth.
Read more →TARSTarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Tarsus Pharmaceuticals, Inc. will host a live webcast on November 4, 2025, to report its third quarter financial results and provide a corporate update. The company is focused on advancing its pipeline in eye care and infectious disease prevention. Notably, its product XDEMVY has received FDA approval for treating Demodex blepharitis.
Read more →TARSDocument Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY launch, an increase of 152% year
Tarsus Pharmaceuticals reported second quarter 2025 financial results with record net product sales of $102.7 million, up 152% from the previous year. The company attributed this growth to an effective direct-to-consumer advertising campaign that boosted patient prescriptions and established XDEMVY as a leading treatment for Demodex blepharitis. Although the company faced a net loss of $20.3 million, they remain optimistic about their long-term growth strategy and pipeline developments. Tarsus plans to discuss these results in a conference call held on August 6, 2025.
Read more →TARSTarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals reported record net product sales of $102.7 million for the second quarter of 2025, marking a significant 152% increase year over year following the launch of XDEMVY for Demodex blepharitis. The company's direct-to-consumer campaign successfully boosted patient engagement and expanded the prescribing base, with over 20,000 eye care professionals prescribing the product. Despite the positive sales growth, Tarsus faced a net loss of $20.3 million, which, while improved from the previous year, raises concerns about rising operational costs. The firm also indicated that its pipeline for future treatments remains promising, with clinical trials set to begin in the upcoming months.
Read more →TARSTarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
Tarsus Pharmaceuticals, Inc. will host a live webcast on August 6, 2025, to report its second quarter 2025 financial results and provide a corporate update. The webcast aims to inform stakeholders about the company's latest developments. Tarsus focuses on innovative treatments, particularly in eye care and infectious diseases. The company has a proven therapeutic approach with its FDA-approved product XDEMVY and ongoing development of other candidates.
Read more →TARSDocument Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements Generated $78.3 million in net product sales of XDEMVY , an increase of 217% year over year and 18% over Q4 2024, and dispense
Tarsus Pharmaceuticals reported a significant increase in net product sales for XDEMVY, achieving $78.3 million for Q1 2025, which is a 217% increase year-over-year. The company's financial position was bolstered by a public equity offering, raising approximately $135 million. Tarsus is also progressing on its clinical pipeline, with plans to initiate a Phase 2 trial for TP-04, aimed at treating Ocular Rosacea, later this year. Overall, Tarsus demonstrates strong momentum in its strategic execution within the eye care sector.
Read more →TARSTarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals reported strong financial results for the first quarter of 2025, with net product sales of XDEMVY reaching $78.3 million, an increase of 217% year over year. The company has bolstered its financial position through a $135 million equity offering and is on track for a Phase 2 trial of TP-04 for Ocular Rosacea. XDEMVY is experiencing widespread commercial reimbursement, covering over 90% of covered lives. Despite a reported net loss, Tarsus continues to make gains with its products and pipeline advancements.
Read more →TARSTarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Tarsus Pharmaceuticals has announced that it will report its first quarter 2025 financial results on May 1, 2025, via a live webcast. This event will provide both financial updates and a corporate overview. Tarsus is known for its commitment to revolutionizing treatments, particularly in eye care and infectious disease prevention, with ongoing developments in its product pipeline. XDEMVY is one of their approved products targeting Demodex blepharitis, while TP-04 and TP-05 are in development for Ocular Rosacea and Lyme disease prevention, respectively.
Read more →TARSTarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting
Tarsus Pharmaceuticals is set to present four data sets at the ASCRS 2025 Annual Meeting, focusing on the prevalence and impact of Demodex blepharitis, as well as the efficacy of its treatment XDEMVY. The accepted abstracts will cover various studies that highlight the global burden of this eyelid disease and the real-world effectiveness of XDEMVY in improving patient outcomes. The event will take place from April 25-28, 2025, in Los Angeles, California, where leading experts will discuss the findings.
Read more →TARSTarsus Announces Pricing of Upsized $125.0 Million Public Offering
Tarsus Pharmaceuticals announced an upsized public offering of 2,808,988 shares priced at $44.50 each, aiming to raise approximately $125 million. The offering includes an option for underwriters to purchase 421,348 additional shares. The transaction is set to close on March 14, 2025, pending standard closing conditions. This funding will support Tarsus's development efforts, including its treatments in eye care and infectious disease prevention.
Read more →TARSTarsus Announces Proposed $100.0 Million Public Offering
Tarsus Pharmaceuticals, Inc. announced a proposed public offering of $100 million of its common stock, with the potential for an additional $15 million. The company plans to use the proceeds to fuel its growth and advance its pipeline in eye care and infectious disease prevention. Although the offering aligns with Tarsus's strategic objectives, its completion is subject to market conditions and other uncertainties.
Read more →TARS▼ -9.3%on this news
Document Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements Generated fourth quarter and full-year 2024 net product sales of XDEMVY of $66.4 million and $180.1 mill
Tarsus Pharmaceuticals reported strong financial results for Q4 and the full year 2024, with net product sales of XDEMVY reaching $66.4 million in the fourth quarter and $180.1 million for the year. The launch of XDEMVY is highlighted as one of the most successful in eye care, creating significant market demand and improving patient outcomes for conditions like Meibomian Gland Disease. The company is also advancing its pipeline, including TP-04 for Ocular Rosacea and plans for further studies with TP-05 for Lyme disease prevention. Tarsus continues to build its executive leadership team to support future growth.
Read more →TARS▼ -9.3%on this news
Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals reported impressive financial results for Q4 and full-year 2024, with net product sales of XDEMVY reaching $66.4 million and $180.1 million, respectively. The company highlighted groundbreaking data from clinical trials showing functional improvements in patients with Meibomian Gland Disease and ongoing advancements in other therapies, including TP-04 for Ocular Rosacea. Tarsus's Direct-To-Consumer campaigns have shown promising initial responses, significantly boosting patient engagement. The company is also progressing in establishing a regulatory pathway for TP-05 aimed at Lyme disease prevention.
Read more →TARSTarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
Tarsus Pharmaceuticals, Inc. will report its fourth quarter and full-year 2024 financial results during a live webcast on February 25, 2025. The event will start at 5:00 a.m. PT / 8:00 a.m. ET, and a recorded version will be available afterward. The company continues to focus on revolutionizing treatment in eye care and infectious disease prevention, with an advancing pipeline including therapies for Ocular Rosacea and Lyme disease prevention.
Read more →TARS▼ -10.8%on this news
The Future of Eye Care Begins Here January 2025 Matt, an XDEMVY Patient Forward-Looking Statements Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding
Tarsus Pharmaceuticals is outlining its forward-looking statements regarding the commercial success of its product XDEMVY for treating Demodex blepharitis. The company anticipates growth driven by its newly expanded sales efforts and direct-to-consumer marketing campaigns. Tarsus is also assessing regulatory pathways for potential international approval and is monitoring clinical study timelines for its pipeline products aiming to address ocular diseases. The management emphasizes the significance of educating the market about Demodex blepharitis and driving product adoption among eye care providers.
Read more →TARS▼ -10.8%on this news
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
Tarsus Pharmaceuticals has outlined its strategic priorities for 2025, focusing on advancing TP-04 for Ocular Rosacea treatment, alongside a successful rollout of XDEMVY. The company reported significant growth in XDEMVY sales and increased physician adoption, setting a strong foundation for future developments. Plans for a Phase 2 study of TP-04 are underway, with results anticipated in 2026. Additionally, Tarsus is expanding its sales force and enhancing market presence through direct-to-consumer advertising.
Read more →TARSTarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals reported robust financial results for the third quarter of 2024, with net product sales of $48.1 million for XDEMVY, an 18% increase from the previous quarter. The company successfully expanded its payer coverage, now reaching over 80% of covered lives, and presented promising clinical data for XDEMVY in addressing eye care conditions. The net loss for the quarter was $23.4 million, though significantly improved compared to the prior year's loss. Tarsus also continues to grow its sales force and strengthen its executive team to position itself for future success.
Read more →TARSTarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
Tarsus Pharmaceuticals has appointed Dr. Kate Goodrich, Chief Medical Officer of Humana, to its Board of Directors. Dr. Goodrich brings over 20 years of experience and a strong background in innovative healthcare initiatives. Her expertise in value-based care is expected to enhance Tarsus's mission to revolutionize ocular treatment. Tarsus continues to focus on unmet needs in healthcare, with ongoing research into several investigational therapies.
Read more →TARSDocument Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements Generated $48.1 million in XDEMVY net product sales driven by more than 41,400 bottles delivered to patients
Tarsus Pharmaceuticals reported strong financial results for Q3 and year-to-date 2024, highlighted by $48.1 million in net product sales for XDEMVY, marking an 18% increase from the previous quarter. The company secured major Medicare contracts, expanding coverage significantly. Notably, recent clinical data showcased meaningful improvements in patient outcomes related to Meibomian Gland Disease. Despite achieving record sales, the company incurred a net loss of $23.4 million, attributed to rising operational expenses.
Read more →TARSTarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
Tarsus Pharmaceuticals, Inc. will announce its third quarter 2024 financial results on November 13, 2024, during a live webcast. The company focuses on innovating treatments for unmet needs, particularly in eye care, and is also advancing its pipeline in dermatology and disease prevention. XDEMVY®, their FDA-approved treatment for Demodex blepharitis, highlights their commitment to leveraging science and technology in healthcare. The webcast will provide insights into their financial performance and corporate updates.
Read more →TARSTarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
Tarsus Pharmaceuticals has appointed Dr. Elizabeth Yeu as Chief Medical Officer, effective November 4, 2024. Dr. Yeu, who has been with Tarsus in various capacities since 2020, will lead the company's Medical Organization focusing on medical affairs and patient safety. Her extensive expertise in ophthalmology is expected to enhance Tarsus' ability to deliver innovative treatments, including the recently launched XDEMVY. Dr. Yeu's arrival marks a strategic move to strengthen the company's leadership in eye care and further develop its pipeline programs.
Read more →TARSTarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25%
Tarsus Pharmaceuticals has launched a direct-to-consumer TV campaign titled 'Your Mitey Problem' for its FDA-approved treatment, XDEMVY (lotilaner ophthalmic solution), targeting Demodex blepharitis. The campaign aims to educate viewers about the condition caused by Demodex mites and is designed to encourage patients to seek consultation with eye care providers. With its innovative approach, the campaign leverages humor and creative visuals to illustrate the impact of the disease, hoping to raise awareness among the approximately 25 million Americans affected by this condition.
Read more →TARSTarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
Tarsus Pharmaceuticals, Inc. announced that its Chief Commercial Officer, Aziz Mottiwala, will participate in a virtual fireside chat at the UBS Virtual Ophthalmology Day 2024 on October 2. The event aims to showcase Tarsus's commitment to addressing unmet needs in patient care, particularly in ophthalmology. Tarsus is advancing several investigational therapies and has FDA approval for XDEMVY for Demodex blepharitis. The event will be accessible via a live webcast, with a replay available on its website shortly afterward.
Read more →TARSTarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
Tarsus Pharmaceuticals, Inc. announced that its CEO Bobby Azamian and CFO Jeff Farrow will participate in an in-person fireside chat at the 2024 Wells Fargo Securities Healthcare Conference on September 4. The event will highlight the company's focus on using science and technology to address unmet needs in healthcare, particularly in eye care. Tarsus is advancing its pipeline of therapies, including XDEMVY® for Demodex blepharitis and several investigational treatments targeting other conditions.
Read more →TARSTarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals reported strong financial performance for Q2 2024, with $40.8 million in net product sales for their eye care product XDEMVY, marking a 65% increase from Q1 2024. The company has expanded its sales force and improved payer coverage, including new Medicare contracts. Despite these positive developments, Tarsus also reported a net loss of $33.3 million, up from $31.4 million in the same period last year, driven by increased operational expenses. The company is on track to further advance its product pipeline and deployment of its sales force.
Read more →TARSDocument Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements Generated $40.8 million in XDEMVY net product sales in the second quarter and $65.5 million year-to-date Del
Tarsus Pharmaceuticals reported robust financial results for Q2 2024, showcasing $40.8 million in net product sales for its eye care treatment, XDEMVY. The company successfully improved its gross-to-net discount to 44%, highlighting strong payer support and expanding coverage. Despite these achievements, Tarsus faced a net loss of $33.3 million for the quarter, a slight increase from the previous year. The company is poised for further growth with an expanding sales force and an upcoming direct-to-consumer campaign.
Read more →TARSTarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Tarsus Pharmaceuticals, Inc. has announced a live webcast on August 8, 2024, to report its financial results for the second quarter of 2024 and to provide a corporate update. The company focuses on unmet medical needs, particularly in eye care and has a pipeline including treatments for Meibomian Gland Disease, rosacea, and Lyme disease. XDEMVY, its FDA-approved product for Demodex blepharitis, highlights its commitment to innovative treatment solutions. Participants can access the webcast through the company's website, with an archived version available for 90 days post-event.
Read more →TARS▼ -8.9%on this news
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
Tarsus Pharmaceuticals, Inc. has announced that its CEO, Bobak Azamian, will participate in a fireside chat at the 2024 Bank of America Healthcare Conference in Las Vegas. The event is scheduled for May 15, 2024. This participation highlights Tarsus's commitment to addressing unmet medical needs through innovative treatments, particularly in eye care. A live webcast of the event will be available on the Tarsus website, along with a replay of the presentation.
Read more →TARSDocument Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements Generated $24.7 million in net product sales of XDEMVY , an 89% increase over Q4 2023, and delivered approximately 26,000 bott
Tarsus Pharmaceuticals reported impressive financial results for Q1 2024, achieving $24.7 million in net product sales of XDEMVY, reflecting a substantial 89% increase from Q4 2023. The company further secured multiple commercial payer contracts aimed at broadening access to the medication by the end of 2024, with Medicare coverage anticipated by 2025. Despite these gains, Tarsus faced a net loss of $35.7 million, representing a considerable increase in expenditures, particularly in selling, general, and administrative costs, compared to the prior year.
Read more →TARSTarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals (TARS) announced its financial results for the first quarter of 2024, showcasing robust performance with $24.7 million in net product sales of XDEMVY, marking an 89% increase from the previous quarter. The company has successfully expanded its sales team and secured significant commercial payer contracts, positioning itself for broad coverage by late 2024. However, Tarsus reported a net loss of $35.7 million for the quarter, indicating ongoing financial challenges despite positive commercial momentum.
Read more →TARSTarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
Tarsus Pharmaceuticals, Inc. will host a live webcast on May 8, 2024, to announce its first quarter financial results and provide a corporate update. The company is focused on innovative treatments, especially in eye care, and is advancing several therapies with unmet medical needs. Among these is XDEMVY, an FDA-approved treatment for Demodex blepharitis. Furthermore, Tarsus has investigational therapies in development for conditions such as Meibomian Gland Disease and Lyme disease.
Read more →TARSdisease prevention. XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-03 as an investigational therapy for the treatm
Tarsus Pharmaceuticals, Inc. has announced a $200 million non-dilutive financing commitment from Pharmakon Advisors, aimed at strengthening its financial position. The company has drawn $75 million immediately, with the remaining funds available through 2025 based on certain conditions. This financing will bolster Tarsus's ongoing development of innovative therapies, such as TP-03 for Meibomian Gland Disease and TP-05 for Lyme disease prevention, as they continue to address significant unmet medical needs in eye care and other therapeutic areas.
Read more →TARSTarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
Tarsus Pharmaceuticals has announced a significant financial development, securing a $200 million commitment from Pharmakon Advisors. The company plans to draw $75 million immediately and retain the option for additional funding in the future based on performance metrics. This non-dilutive financing enables Tarsus to further its mission in addressing unmet medical needs, particularly in eye care. The new credit facility will support continued growth without placing additional financial burdens on the company through covenants or warrants.
Read more →TARSTarsus to Participate at Upcoming Investor Conferences
Tarsus Pharmaceuticals, Inc. has announced its participation in several upcoming investor conferences, including the Guggenheim Healthy Altitudes Summit and the Barclays Global Healthcare Conference. Key executives from the company will engage in fireside chats and one-on-one meetings, providing insights into the company's advancements and strategies. Tarsus is focused on developing therapies for unmet needs, especially in eye care and dermatology, and is advancing its pipeline with several Phase 2 investigational therapies. The company encourages investors to check its website for updates on conference details.
Read more →TARSTarsus Introduces “Mite Party” Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
Tarsus Pharmaceuticals has launched the 'Mite Party' campaign to raise awareness about Demodex blepharitis and promote XDEMVY (lotilaner ophthalmic solution), the first FDA-approved treatment for the disease. The campaign aims to educate consumers and encourage screenings through relatable messaging and visuals. Kicking off with a Facebook LIVE event, the initiative highlights the clinical significance of Demodex blepharitis, which affects about 25 million adults in the U.S. The campaign also includes a 'Find a Doctor' tool and other educational resources to facilitate patient-provider conversations.
Read more →TARSTarsus Announces Pricing of $100.0 Million Public Offering
Tarsus Pharmaceuticals announced the pricing of a public offering of 2,812,500 shares of common stock at $32.00 per share, aiming to raise approximately $100 million. An additional option allows underwriters to purchase an extra 468,750 shares at the same price. The closing of the offering is anticipated on March 5, 2024, contingent upon regular closing conditions. This offering is part of Tarsus’s strategy to enhance its operations in addressing unmet medical needs, particularly in eye care and other therapeutic areas.
Read more →TARS▲ +18.3%on this newsshared move
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals reported a strong financial performance for Q4 and full-year 2023, attributed primarily to the successful launch and sales of XDEMVY. The company achieved net product sales of $13.1 million in Q4 and delivered over 17,400 bottles of the new product to patients. Alongside sales growth, Tarsus also advanced its clinical pipeline, reporting positive initial results from several Phase 2a trials. However, the company recorded a significant net loss, which was higher than the previous year's, largely due to escalating R&D and SG&A costs.
Read more →TARS▲ +18.3%on this newsshared move
Document Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements Launched XDEMVY (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and gene
Tarsus Pharmaceuticals reported strong financial results for Q4 2023 and the full year, highlighting the successful launch of XDEMVY, an ophthalmic solution for Demodex blepharitis. The company generated significant net product sales and witnessed a positive market response, with over 17,400 bottles delivered to patients. However, Tarsus also reported a substantial net loss of $135.9 million for the year, driven largely by increased sales and administrative expenses. This performance reflects both the successful introduction of new treatments and the challenges of scaling operations.
Read more →TARSTarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
Tarsus Pharmaceuticals announced positive topline results from the Phase 2a Carpo trial of TP-05 (lotilaner), an investigational oral treatment for Lyme disease prevention. In this study, both high and low doses of TP-05 significantly outperformed placebo in killing ticks within 24 hours post-attachment, achieving mean mortality rates of up to 97%. With Lyme disease posing significant public health concerns, these findings could lead to a novel therapeutic solution to prevent transmission. The treatment was well tolerated, and the results encourage further development as a non-vaccine option for tick-borne disease prevention.
Read more →TARSTarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
Tarsus Pharmaceuticals, Inc. has announced that it will host a live webcast on February 27, 2024, to report its financial results for the fourth quarter and full year of 2023, along with a corporate update. The company is known for addressing unmet medical needs in eye care and other therapeutic areas. Tarsus currently has several products in development, including TP-03 for Meibomian Gland Disease and TP-04 for rosacea, alongside its FDA-approved treatment XDEMVY.
Read more →TARSTarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
Tarsus Pharmaceuticals, Inc. announced that its CEO, Bobak Azamian, will participate in a fireside chat at the Sixth Annual Guggenheim Healthcare Talks conference on February 8, 2024. The event will be accessible via live webcast, with replays available shortly after. Tarsus is working on advancing its pipeline, which includes several therapies for unmet medical needs in eye care, dermatology, and disease prevention, notably including XDEMVY for Demodex blepharitis and ongoing clinical trials for TP-03, TP-04, and TP-05.
Read more →TARSTarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
Tarsus Pharmaceuticals has reported positive topline results from the Ersa Phase 2a clinical trial for TP-03, aimed at treating Meibomian Gland Disease in patients with Demodex mites. The study demonstrated significant improvements in both the Meibomian Gland Secretion Score and the number of glands secreting clear liquid. TP-03 was well tolerated, and no differences were noted between the dosage arms. The company is optimistic about the drug's potential and plans further data analysis and discussions with the FDA.
Read more →TARS▼ -5.9%on this news
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals reported its third quarter 2023 results, highlighting significant developments including the launch of XDEMVY, the first FDA-approved treatment for Demodex blepharitis. The company generated $1.7 million in net product sales following XDEMVY's launch in late August. Despite this positive momentum, Tarsus reported a net loss of $39.1 million, reflecting the high costs associated with its commercial launch and continued research and development efforts. The company also successfully fortified its financial position with a $100 million public equity offering.
Read more →TARS▼ -5.9%on this news
Document Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements Launched XDEMVY (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis Achieved $1.7 million in net p
Tarsus Pharmaceuticals announced financial results for Q3 2023, highlighting the successful launch of XDEMVY, an eye drop treatment for Demodex blepharitis. The company reported $1.7 million in product sales, with over 1,700 bottles dispensed since the product's launch. Despite these achievements, Tarsus faced a net loss of $39.1 million, which is significantly higher than the previous year's loss for the same quarter. Ongoing financial strengthening efforts included a $100 million public equity offering aimed at bolstering their balance sheet.
Read more →TARSTarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
Tarsus Pharmaceuticals, Inc. will host a live webcast on November 9, 2023, at 1:30 p.m. PT to report its third quarter financial results and provide a corporate update. The webcast, along with additional information, will be accessible on Tarsus' website. The company's initiatives include various therapeutic developments in eye care, dermatology, and infectious disease prevention, highlighting its commitment to addressing unmet medical needs.
Read more →TARSTarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
Tarsus Pharmaceuticals celebrated the launch of XDEMVY, the first FDA-approved treatment for Demodex blepharitis, by ringing the Nasdaq closing bell. The eye drops are now available nationwide, addressing a significant clinical need for patients suffering from this common eyelid condition. XDEMVY demonstrated strong efficacy and safety in pivotal trials with over 800 participants. The CEO expressed gratitude to the team and supporters during this milestone event.
Read more →TARSTarsus to Present at Upcoming Investor Conferences
Tarsus Pharmaceuticals, Inc. announced that its CEO and CFO will participate in upcoming investor conferences in New York City. These conferences include the H.C. Wainwright 25th Annual Global Investment Conference and the Morgan Stanley 21st Annual Global Healthcare Conference. The company's mission focuses on addressing unmet needs through innovation in eye care, and it continues to advance its pipeline of investigational medicines, including therapies for various conditions. Live webcasts of the presentations will be available on Tarsus's website, ensuring accessibility for interested stakeholders.
Read more →TARSDocument Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements XDEMVY (lotilaner ophthalmic solution) 0.25% received FDA approval for the treatment for Demodex blepharitis On track to have
Tarsus Pharmaceuticals recently reported its second quarter 2023 financial results, highlighting the FDA approval of XDEMVY (lotilaner ophthalmic solution) for Demodex blepharitis. The company plans to launch XDEMVY by the end of August 2023, alongside a newly established sales force targeting eye care practitioners. Financially, Tarsus faced increased losses compared to the previous year, primarily due to decreased collaboration revenue and rising operating costs. Despite this, Tarsus is well-funded, with a strong pipeline aimed at addressing unmet needs in eye care and other therapeutic areas.
Read more →TARSTarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals announced its second quarter 2023 financial results, highlighting the FDA approval of XDEMVY for Demodex blepharitis. The company is on track to launch XDEMVY by the end of August 2023 and has recently strengthened its financial position through a public equity offering. However, despite the positive developments, Tarsus reported a significant net loss compared to the previous year, largely due to a decrease in revenue and increased expenses. The company continues to prepare for strong market entry and seeks to educate eye care providers on the new treatment.
Read more →TARS▼ -5.5%on this news
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
Tarsus Pharmaceuticals, Inc. has announced the pricing of an underwritten public offering of 5,714,285 shares of common stock at a price of $17.50 per share, aiming to raise approximately $100 million. The offering is expected to close on August 4, 2023, subject to customary conditions. Major financial institutions, including Goldman Sachs and BofA Securities, are managing the offering. Tarsus continues to advance its therapeutics in eye care and other areas, including dermatology and infectious disease prevention.
Read more →TARSTarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
Tarsus Pharmaceuticals has announced a proposed underwritten public offering of $100 million in shares of its common stock. In addition, the company plans to offer underwriters a 30-day option to purchase an extra $15 million in shares. This move is part of Tarsus's ongoing efforts to secure funding for its projects aimed at tackling unmet needs in eye care and other therapeutic areas. However, the offering is subject to market conditions, and specifics regarding its completion remain uncertain.
Read more →TARSTarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
Tarsus Pharmaceuticals, Inc. announced it will host a virtual investor webcast to discuss its commercialization strategy for TP-03, a potential treatment for Demodex blepharitis. The event is scheduled for June 15, 2023, and will provide an overview of plans and progress related to TP-03, which has shown positive results in clinical trials. Additionally, an FDA New Drug Application for TP-03 has been accepted with a decision expected by August 25, 2023. Tarsus is also developing other investigational therapies for different medical conditions.
Read more →TARSTarsus to Present at the Jefferies Global Healthcare Conference
Tarsus Pharmaceuticals, Inc. announced its participation in the Jefferies Global Healthcare Conference with CEO Bobak Azamian scheduled for an in-person Fireside Chat. The event will take place on June 7, 2023, in New York. Tarsus is advancing its drug candidates, particularly TP-03, which has shown promise for treating Demodex blepharitis and has received FDA acceptance for its New Drug Application, with an action date of August 25, 2023. The company also has other investigational medicines in clinical trials for various conditions including Rosacea and Lyme disease.
Read more →TARSTarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements
Continuing to build market awareness through disease education and deploying commercial leadership in anticipation of TP-03 August 25, 2023 PDUFA Presented health economics data suggesting a costly and substantial burden of illness in patients with Demodex blepharitis Tarsus to
Read more →TARSDocument Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements Continuing to build market awareness through disease education and deploying commercial leadership in anticipation of TP-03
Tarsus Pharmaceuticals has reported its financial results for Q1 2023, highlighting a net loss of $23.4 million, up from $20.2 million in Q1 2022. The company is focused on advancing its product candidate, TP-03, aimed at treating Demodex blepharitis, which has a PDUFA target action date of August 25, 2023. In addition, they are engaging in extensive disease education campaigns to build market awareness. Progress on their other product candidates TP-04 and TP-05 continues, with ongoing clinical trials underway. A webcast is scheduled for June 15, 2023, to further discuss commercialization strategy and updates.
Read more →TARSTarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers
Demodex blepharitis is a highly prevalent, yet often undiagnosed eyelid disease that impacts approximately 25 million eye care patients in the U.S. IRVINE, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet ne
Read more →TARSTarsus to Participate at the Bank of America 2023 Healthcare Conference
IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian,
Read more →TARSTarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer
IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of
Read more →TARSDocument Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements Engaging with more than two-thirds of key optometrists and or ophthalmologists, and top payers on Demodex blepharitis in anticipat
Tarsus Pharmaceuticals reported full-year 2022 financial results and highlighted key developments in its pipeline, particularly regarding TP-03 for Demodex blepharitis. The FDA has accepted the New Drug Application for TP-03, with a target action date set for August 25, 2023. Additionally, Tarsus completed enrollment in its Phase 2a trials for Meibomian Gland Disease and initiated another trial for rosacea. Despite an increase in net loss and operational costs, the company expects sufficient cash flow to support its initiatives through at least 2026.
Read more →TARSTarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements
Engaging with more than two-thirds of key optometrists and/or ophthalmologists, and top payers on Demodex blepharitis in anticipation of TP-03 August 25, 2023 PDUFA Completed enrollment of Ersa, a Phase 2a trial evaluating TP-03 for MGD with topline data expected in 2H 2023 and
Read more →TARSTarsus Added to NASDAQ Biotechnology Index
IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Tarsus will be
Read more →TARSTarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
Positive Phase 1b Callisto data shows that TP-05 is well tolerated and safety data supports progression to Phase 2a Phase 2a Carpo trial to evaluate the safety, tolerability, and proof-of-activity of TP-05 in healthy subjects TP-05 designed to be an on-demand, long-acting proph
Read more →TARSDocument Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements New Drug Application for TP-03 accepted PDUFA target action date
Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements New Drug Application for TP-03 accepted PDUFA target action date August 25, 2023 Launched disease education, field medical team and payor engagement in anticipation of TP-03 launch Cash runway
Read more →TARSTarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements
New Drug Application for TP-03 accepted; PDUFA target action date August 25, 2023 Launched disease education, field medical team and payor engagement in anticipation of TP-03 launch Cash runway anticipated into at least 2026 for the planned commercial launch of TP-03 and contin
Read more →TARSTarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus recently submitted NDA to the FDA for TP-03 Data from an investigator-initiated trial evaluating meibomian gland atrophy in patients with Demodex blepharitis will also be presented
Read more →TARSTarsus Announces Transition Plans for Board of Directors
Co-founder and Chairman Michael Ackermann plans to transition off Board of Directors Wendy Yarno will become Lead Independent Director and CEO Bobak Azamian will become Chairman upon Dr. Ackermann’s expected transition IRVINE, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Tarsus Ph
Read more →TARSTarsus Appoints Scott Morrison as Board Member and Audit Committee Chair
Mr. Morrison brings over 40 years of financial and operational expertise in life sciences IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address unmet patient needs, starting with eye care, through the applicati
Read more →TARSTarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis
Demodex blepharitis is a highly prevalent, yet often missed or misdiagnosed lid margin disease that impacts approximately 25 million eye care patients in the U.S. IRVINE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to
Read more →TARSTarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings
Positive data to be presented at WCC VIII and AAO 2022 conferences in Chicago Tarsus recently submitted NDA to the FDA for TP-03 IRVINE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply pr
Read more →TARSTarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis
IRVINE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has submit
Read more →TARSDocument Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial NDA submission expected this y
Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial NDA submission expected this year Initiated Ersa Phase 2a trial evaluating TP-03 for the treatmen
Read more →TARSTarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements
TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; NDA submission expected this year Initiated Ersa Phase 2a trial evaluating TP-03 for the treatment of Meibomian Gland Disease Cash runway anticipated into at least 2026 for the comme
Read more →TARSTarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease
IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has enrolle
Read more →TARSTarsus to Present at the Jefferies 2022 Healthcare Conference
IRVINE, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian,
Read more →TARS▲ +11.3%on this news
Document Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial anticipated NDA submission in t
Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial anticipated NDA submission in the second half of this year Cash runway expected into at least 2026
Read more →TARS▲ +11.3%on this news
Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements
TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; anticipated NDA submission in the second half of this year Cash runway expected into at least 2026 IRVINE, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASD
Read more →TARS▼ -8%on this newsshared move
Tarsus to Present at Bank of America 2022 Healthcare Conference
IRVINE, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian,
Read more →TARS▼ -6.7%on this newsshared move
Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting
IRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, presented data from its Atlas Contin
Read more →TARS▼ -6.8%on this news· ran to -21% by day 3shared move
Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock
IRVINE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today an
Read more →TARS▼ -23.5%on this news· ran to -34% by day 3shared move
Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock
Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock IRVINE, Calif., May 2, 2022 Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) (the Company or Tarsus ), whose mission is to focus on unmet needs and apply proven science and new technolog
Read more →TARS▼ -23.5%on this news· ran to -34% by day 3shared move
Legal Disclaimer This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are
May 2022 Saturn-2 Phase 3 Pivotal Trial Topline Data Presentation and Corporate Update Tarsus Pharmaceuticals 2022 Exhibit 99.1 Legal Disclaimer This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither h
Read more →TARS▼ -23.5%on this news· ran to -34% by day 3shared move
TP-03 Met All Primary and Secondary Endpoints Again in Saturn-2, with a Complete Resolution of Demodex Blepharitis Efficacy: Met all pre-specified primary and secondary endpoints Primary Endpoint: Complete Collarette Cur
Saturn-2 Phase 3 Topline Data Tarsus Pharmaceuticals 2022 Exhibit 99.1 TP-03 Met All Primary and Secondary Endpoints Again in Saturn-2, with a Complete Resolution of Demodex Blepharitis Efficacy: Met all pre-specified primary and secondary endpoints Primary Endpoint: Complete
Read more →TARS▼ -23.5%on this news· ran to -34% by day 3shared move
Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year
TP-03 met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related adverse events 56% of patients on TP-03 achieved the primary endpoint of complete collarette cure Webcast today at 8:00 a.m. ET t
Read more →TARS▼ -23.5%on this news· ran to -34% by day 3shared move
Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis
IRVINE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, will hold a webcast on Monday, May
Read more →TARSTarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting
IRVINE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, presented data yesterday from its
Read more →TARS▼ -5.9%on this news
Document Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements Expecting Saturn-2 Phase 3 topline data in April 2022, the second pivotal of TP-03 for the treatment of Demo
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements Expecting Saturn-2 Phase 3 topline data in April 2022, the second pivotal of TP-03 for the treatment of Demodex blepharitis, and NDA submission this year Advancing pipeline th
Read more →TARS▼ -5.9%on this news
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements
Expecting Saturn-2 Phase 3 topline data in April 2022, the second pivotal of TP-03 for the treatment of Demodex blepharitis, and NDA submission this year Advancing pipeline this year with planned Phase 2 initiations of TP-03 for Meibomian Gland Disease and TP-04 for Rosacea, and
Read more →TARS▼ -14.1%on this news
Tarsus to Host Eye Care Leaders Webcast on Unmet Needs in Demodex Blepharitis and Potential of TP-03
Revolutionizing Treatment for Demodex Blepharitis Patients event to feature Eric Donnenfeld, M.D.; Paul Karpecki, O.D.; and Elizabeth Yeu, M.D. Webcast scheduled for Tuesday, February 8, 2022 at 9 a.m. Pacific Time IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharma
Read more →TARS▼ -14.1%on this news
Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures $175 Million Credit Facility
Topline data expected in April 2022 from Saturn-2, the second Phase 3 pivotal trial of TP-03 and NDA submission remains on track for this year Credit facility with Hercules Capital and Silicon Valley Bank provides availability of non-dilutive capital IRVINE, Calif., Feb. 02, 20
Read more →TARSDocument Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors Dr. Yeu brings over 20 years of eye care experience, and is a highly regarded leader in
Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors Dr. Yeu brings over 20 years of eye care experience, and is a highly regarded leader in clinical care and new product innovation IRVINE, Calif., January 4
Read more →TARSTarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors
Dr. Yeu brings over 20 years of eye care experience, and is a highly regarded leader in clinical care and new product innovation IRVINE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply prov
Read more →TARS▲ +7.7%on this news
Tarsus to Participate at Upcoming Virtual Investor Conferences
IRVINE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management wil
Read more →TARSTarsus to Participate in the Virtual Jefferies London Healthcare Conference 2021
IRVINE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian,
Read more →TARSDocument Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements On track to complete enrollment in the fourth quarter of 2021 for the Saturn-2 Phase 3, the second pivot
Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements On track to complete enrollment in the fourth quarter of 2021 for the Saturn-2 Phase 3, the second pivotal trial of TP-03 for the treatment of Demodex blepharitis topline d
Read more →TARSTarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements
On track to complete enrollment in the fourth quarter of 2021 for the Saturn-2 Phase 3, the second pivotal trial of TP-03 for the treatment of Demodex blepharitis; topline data expected in the first quarter of 2022 Data from two pioneering studies on prevalence and impact of Dem
Read more →TARSTarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting
Titan real-world prevalence study data reveals that Demodex blepharitis accounts for over two-thirds of all blepharitis cases and is highly prevalent in many commonly seen patient groups New Titan study data analysis showed that current management tools, such as tea tree oil (TT
Read more →TARS▼ -5.5%on this newsshared move
Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare Conference
IRVINE, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian,
Read more →TARSTarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of Directors Ms. Crane brings over 30 years of experience in executive leadership, commercialization, and bus
Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Ms. Crane brings over 30 years of experience in executive leadership, commercialization, and business development in the pharmaceutical and healthcare industries IRVINE, Ca
Read more →TARSTarsus Medical Group Announces the Acquisition of the International Peptide Society
Boca Raton, FL, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Tarsus Medical Group Announces the Acquisition of the International Peptide Society The acquisition marks a valuable move for Tarsus Medical Group into the rapidly growing field of peptides. Tarsus Medical Group, the leading glo
Read more →TARSDocument Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates Announced positive results of the Saturn-1 pivotal trial evaluating TP-03 for the treatment o
Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates Announced positive results of the Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis results presented at the 2021 American Society
Read more →TARSTarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates
Announced positive results of the Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis; results presented at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) conference Initiated Saturn-2, second pivotal Phase 3 trial evaluating th
Read more →TARSTarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021
New Saturn-1 data demonstrated a strong patient responder rate with 95% of Demodex blepharitis patients treated with TP-03 achieving ≤0.5 mites per lash and 93% improving by at least one collarette grade Further Saturn-1 safety analysis revealed that TP-03 had a favorable safety
Read more →TARSTarsus Pharmaceuticals, Inc. to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
IRVINE, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting wi
Read more →TARSTarsus Pharmaceuticals, Inc. to Participate in the Raymond James 2021 Human Health Innovation Conference
IRVINE, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting wi
Read more →TARSTarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstra
Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstrated significant, clinically meaningful outcomes with no se
Read more →TARSTarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast to Announce Saturn-1 Phase 2b/3 Pivotal Trial Results for TP-03 for the Treatment of Demodex Blepharitis
IRVINE, Calif., June 18, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting wi
Read more →TARSTarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease
More than 30 million Americans at risk for Lyme disease exposure, which can result in severe neurological and other debilitating symptoms First participants dosed in single ascending dose and multiple ascending dose (SAD/MAD) trial to evaluate safety, tolerability and pharmacoki
Read more →TARSTarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual Healthcare Conference
IRVINE, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting wit
Read more →TARSDocument Tarsus Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business and Clinical Updates Initiated Saturn-2, second pivotal Phase 3 trial evaluating the safety and efficacy of TP-03 f
Tarsus Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business and Clinical Updates Initiated Saturn-2, second pivotal Phase 3 trial evaluating the safety and efficacy of TP-03 for the treatment of Demodex blepharitis topline data from Saturn-1 e
Read more →TARSTarsus Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business and Clinical Updates
Initiated Saturn-2, second pivotal Phase 3 trial evaluating the safety and efficacy of TP-03 for the treatment of Demodex blepharitis; topline data from Saturn-1 expected this July Announced FDA acceptance of IND for TP-05, a novel candidate in development that aims to be first
Read more →TARSTarsus Pharmaceuticals, Inc. Initiates Saturn-2, Second Pivotal Phase 3 Trial Evaluating the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Demodex blepharitis may affect up to 25 million Americans and result in significant clinical, functional and psychosocial burden for patients Saturn-2 trial design similar to Saturn-1, first pivotal trial for TP-03 Topline data from Saturn-1 expected this July IRVINE, Calif.,
Read more →TARSTarsus Pharmaceuticals, Inc. Announces FDA Acceptance of Investigational New Drug Application for TP-05 for Lyme Disease Prevention
Novel candidate in development aims to be first approved non-vaccine therapeutic for Lyme disease prevention Allows initiation of Phase 1 study to evaluate safety, pharmacokinetics, and dosing More than 30 million Americans at risk for Lyme disease exposure, which can result in
Read more →TARSTarsus Pharmaceuticals, Inc. Presents Results of Pioneering Atlas Study at ARVO 2021 Annual Meeting Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitis
Demodex blepharitis is a common ocular condition that may affect up to 25 million Americans Atlas study shows that Demodex blepharitis negatively impacts daily life for 80 percent of patients Tarsus also presents complete efficacy and safety data from Phase 2b Europa trial, pos
Read more →TARSTarsus Pharmaceuticals, Inc. to Present at the BofA Securities 2021 Virtual Health Care Conference
IRVINE, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting w
Read more →TARSDocument Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis initia
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis initiation of Saturn-2 expected in Q2 2021 Strategic partnership with Lia
Read more →TARSTarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates
Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis; initiation of Saturn-2 expected in Q2 2021 Strategic partnership with LianBio in March 2021 for TP-03 in Greater China provides Tarsus with $70 million expected during next 12 m
Read more →TARSTarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease
IRVINE, Calif., SHANGHAI, China and PRINCETON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company, and LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients
Read more →TARSTarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease Deal expands access
Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease Deal expands access to TP-03 for approximately 40 million patients with Demodex blepharitis
Read more →TARSTarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel
IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseas
Read more →TARSTarsus Pharmaceuticals, Inc. Appoints Dianne Whitfield as Chief Human Resources Officer
IRVINE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseas
Read more →TARSTarsus Pharmaceuticals, Inc. to Present at the 2021 ICR Virtual Conference
IRVINE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseas
Read more →TARSTarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03
IRVINE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseas
Read more →TARSTarsus Pharmaceuticals, Inc. Announces Inclusion in the Russell 3000 Index and Russell 2000 Index
IRVINE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseas
Read more →TARSTarsus Pharmaceuticals, Inc. Appoints Wendy Yarno to Board of Directors
Tarsus Pharmaceuticals, Inc. Appoints Wendy Yarno to Board of Directors IRVINE, Calif., Nov. 19, 2020 GlobeNewswire Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to t
Read more →TARSTarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference
IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus” NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treat
Read more →TARSTarsus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise by the Underwriters of Option to Purchase Additional Shares
IRVINE, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus”), a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic cond
Read more →TARSTarsus Pharmaceuticals Inc. Announces Pricing of Initial Public Offering
IRVINE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc., (“Tarsus”) a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic cond
Read more →Competitive Position
How TARS ranks across every disease it competes inCompetitive Position is a premium feature
See how TARS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial